Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy

Clin Auton Res. 2003 Feb;13(1):51-3. doi: 10.1007/s10286-003-0034-5.

Abstract

In 5 patients with multiple system atrophy, administration of 15 mg/day of amezinium metilsulfate, an adrenergic agent, during 6 months for the treatment of postural hypotension exacerbated post-micturition residuals as compared to that before treatment (178 ml versus 113 ml for a change of 37 %, p < 0.05). Amezinium metilsulfate most probably stimulates both alpha1B-receptors in the vascular wall and alpha1A/D-receptors in the proximal urethra.

MeSH terms

  • Aged
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple System Atrophy / complications*
  • Pyridazines / adverse effects*
  • Pyridazines / therapeutic use
  • Retrospective Studies
  • Sympathomimetics / adverse effects*
  • Sympathomimetics / therapeutic use
  • Urinary Retention / chemically induced*
  • Urodynamics / drug effects
  • Urodynamics / physiology

Substances

  • Pyridazines
  • Sympathomimetics
  • amezinium